ADXS Overview
Upcoming Projects (ADXS)
-
Don’t see a project related to the company you care about? Create your own!
Upcoming & Overdue Catalysts (ADXS)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (ADXS)
-
Advaxis’ (ADXS) ADXS-503 (HOT Lung) Tumor Control Data from Ongoing Phase 1/2 Lung Cancer Trial Released
Ticker: ADXS
Occurred on: Oct 26, 2020 -
FDA accepts IND for Advaxis' (ADXS) drug candidate, ADXS-503, a Phase 1/2 for the treatment of non-small cell lung cancer (NSCLC)
Ticker: ADXS
Occurred on: Jul 30, 2018 -
Advaxis (ADXS) Announces Clinical Hold In Axalimogene Filolisbac Phase 1/2 Combination Study With AstraZeneca’s IMFINZI (Durvalumab)
Ticker: ADXS
Occurred on: Mar 12, 2018 -
FDA Grants Special Protocol Assessment to Advaxis’ Phase 3 Study of AXAL in Patients with Cervical Cancer
Ticker: ADXS
Occurred on: Jul 06, 2016 -
Advaxis Combination Trial with Merck Completes First Two Dose-Escalation Cohorts
Tickers: ADXS, MRK
Occurred on: Apr 05, 2016 -
Dosing Begins in High Dose Expansion Cohort in Phase 2 Study of Axalimogene Filolisbac in Patients With Recurrent Cervical Cancer
Ticker: ADXS
Occurred on: Mar 07, 2016 -
Advaxis (ADXS) to Present on Lm technology at the Jefferies Autumn 2015 Global Healthcare Conference
Ticker: ADXS
Occurred on: Nov 19, 2015
Strategic Initiatives (ADXS)
-
Advaxis (ADXS) Announces Out-Licensing Deal of Lm-Based Antigen Delivery Technology with SELLAS to Develop a Novel Cancer Immunotherapy Agent
Tickers: ADXS, SELLAS Life Sciences Group
Announcement Date: Feb 27, 2017
